Skip to main content

Table 3 Association of PD-L1 staining with clinicopathologic factors in triple-negative patients without neoadjuvant chemotherapy

From: Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

 TCTCICICsTIL level
FactorsNegativePositiveFisherNegativePositiveFisherNegativePositiveFisherLowHighFisher
N (%)N (%)P valueN (%)N (%)P valueN (%)N (%)P valueN (%)N (%)P value
Age[N = 60] [N = 59] [N = 59] [N = 59] 
 < 50 years13 (87)2 (13)0.633911 (79)3 (21)0.516311 (79)3 (21)0.51636 (43)8 (57)0.5378
 ≥ 50 years41 (91)4 (9) 30 (67)15 (33) 30 (67)15 (33) 15 (33)30 (67) 
Race/ethnicity[N = 60] [N = 59] [N = 59] [N = 59] 
 Black13 (81)3 (19)0.39666 (38)10 (63)0.0036 (38)10 (63)0.0033 (19)13 (81)0.1211
 White+Latino40 (93)3 (7) 34 (81)8 (19) 34 (81)8 (19) 17 (40)25 (60) 
 Others1 (100)0 (0) 1 (100)0 (0) 1 (100)0 (0) 1 (100)0 (0) 
Histologic type[N = 59] [N = 58] [N = 58] [N = 58] 
 IDC53 (90)6 (10)NA40 (69)18 (31)NA40 (69)18 (31)NA20 (34)38 (66)NA
 Metaplastic0 (0)0 (0) 0 (0)0 (0) 0 (0)0 (0) 0 (0)0 (0) 
Histologic grade[N = 59] [N = 58] [N = 58] [N = 58] 
 211 (100)0 (0)0.5828 (73)3 (27)18 (73)3 (27)15 (45)6 (55)0.4866
 342 (88)6 (13) 32 (68)15 (32) 32 (68)15 (32) 15 (32)32 (68) 
sTIL level[N = 59] [N = 59] [N = 59] NA 
 < 10%21 (100)0 (0)0.079621 (100)0 (0)0.000121 (100)0 (0)0.0001   
 ≥ 10%32 (84)6 (16) 20 (53)18 (47) 20 (53)18 (47)    
Tumor size[N = 59] [N = 58] [N = 58] [N = 58] 
 ≤ 2 cm31 (97)1 (3)0.1425 (78)7 (22)0.114425 (78)7 (22)0.114414 (44)18 (56)0.2326
 > 2 to 5 cm19 (83)4 (17) 14 (61)9 (39) 14 (61)9 (39) 6 (26)17 (74) 
 > 5 cm3 (75)1 (25) 1 (33)2 (67) 1 (33)2 (67) 0 (0)3 (100) 
pN[N = 59] [N = 58] [N = 58] [N = 58] 
 (y)pN037 (90)4 (10)0.783830 (73)11 (27)0.55930 (73)11 (27)0.55915 (37)26 (63)0.4834
 (y)pN111 (85)2 (15) 7 (54)6 (46) 7 (54)6 (46) 3 (23)10 (77) 
 (y)pN23 (100)0 (0) 2 (67)1 (33) 2 (67)1 (33) 1 (33)2 (67) 
 (y)pN32 (100)0 (0) 1 (100)0 (0) 1 (100)0 (0) 1 (100)0 (0) 
pM[N = 59] [N = 58] [N = 58] [N = 58] 
 051 (89)6 (11)139 (68)18 (32)139 (68)18 (32)120 (35)37 (65)1
 12 (100)0 (0) 1 (100)0 (0) 1 (100)0 (0) 0 (0)1 (100) 
pStage[N = 57] [N = 56] [N = 56] [N = 56] 
 I26 (93)2 (7)0.626422 (79)6 (21)0.393222 (79)6 (21)0.393212 (43)16 (57)0.437
 II19 (86)3 (14) 13 (59)9 (41) 13 (59)9 (41) 5 (23)17 (77) 
 III4 (80)1 (20) 3 (60)2 (40) 3 (60)2 (40) 2 (40)3 (60) 
 IV2 (100)0 (0) 1 (100)0 (0) 1 (100)0 (0) 0 (0)1 (100) 
  1. IDC invasive ductal carcinoma, sTIL stromal tumor infiltrating lymphocytes